News

Merck (NYSE:MRK) reported positive Phase 3 results for its antibody drug conjugate sacituzumab tirumotecan in advanced endometrial cancer and in lung cancer combinations. The company said sacituzumab tirumotecan surpassed standard chemotherapy in advanced endometrial cancer, a first for an ADC in this setting. Merck also highlighted that KEYTRUDA combination regimens received key regulatory recommendations in the EU for frontline perioperative use in muscle invasive bladder cancer. For...

Merck & Co. Inc. (NYSE:MRK) is one of the best low risk stocks to buy in 2026. On May 18, Merck announced that its pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT) met its dual primary endpoints of overall survival/OS and progression-free survival/PFS in patients with advanced or recurrent endometrial cancer. The investigational TROP2-directed […]

Investing.com -- The United States has suspended visa issuance for any travelers who have visited South Sudan, the Democratic Republic of Congo (DRC), or Uganda within 21 days of their planned arrival, according to an exclusive report by The Wall Street Journal on Friday.

The healthcare sector outperformed the rest of the market over the past week.

US equity indexes rose as pressure on government bond yields eased and crude oil retreated from intr

The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.42%. June E-mini S&P futures (ESM26 ) rose +0.35%, and June E-mini Nasdaq futures...

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index advancing 1.1% and the

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index advancing 0.8% and the State

US equity indexes rose as pressure on government bond yields eased and crude oil retreated from intr

The S&P 500 Index ($SPX ) (SPY ) today is up +0.50%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.73%. June E-mini S&P futures (ESM26 ) are up +0.47%, and June E-mini Nasdaq futures...

Merck's Gardasil sales plunge as weak China demand, inventory issues and softer Japan trends cloud the vaccine's overall growth outlook in 2026.

Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.

Merck’s KEYTRUDA + Padcev Bladder Cancer Combination Edges Closer To EU Approval.

Summit Therapeutics advances ivonescimab with late-stage NSCLC and CRC studies, with FDA review underway and new partnerships expanding its oncology reach.

Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.

Stock Market Today: The Dow Jones index rose Friday ahead of a key inflation survey. AMD stock rallied near record highs.

The United States market has experienced a flat week but has shown significant growth over the past year with a 27% increase, and earnings are anticipated to grow by 17% annually. In this context, identifying stocks that may be trading below their estimated value can offer opportunities for investors seeking to capitalize on potential future gains.

FEATURE Stock futures pointed higher Friday as investors remained cautiously optimistic a deal to end the stalemate between the U.S. and Iran could be reached. These stocks were moving in premarket trading: Estee Lauder rose 10%.

Merck has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.8%. The stock now trades at $113.99, marking a 20% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.

Exelixis (EXEL) is back in the spotlight after announcing a clinical development collaboration with Merck to test zanzalintinib plus subcutaneous Keytruda in the planned phase 3 STELLAR-316 colorectal cancer trial. See our latest analysis for Exelixis. For context, Exelixis shares trade at US$49.90, with a 1 month share price return of 14.42% and a year to date share price return of 14.50%. The 3 year total shareholder return of 158.21% points to strong longer term momentum that recent...

LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.

Eisai’s updated analyst model now points to a fair value price target of ¥5,076.92, compared with the prior ¥5,009.23, giving you a fresh reference point for how the stock is being framed today. Bullish and bearish analysts are reading this shift differently, with some seeing the new target as confirmation that the existing case still holds, and others viewing the change as a sign that potential upside could be more limited if the company simply tracks current assumptions. As you read on, you...

Over the last 7 days, the United States market has remained flat, yet it has seen an impressive 27% increase over the past year with earnings projected to grow by 17% per annum in the coming years. In this context of robust growth expectations, dividend stocks that offer stability and consistent income can be attractive options for investors seeking to capitalize on these favorable conditions.

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has built its reputation on paying reliable, growing quarterly distributions to income investors, and the latest data confirms why holders trust the fund. SCHD paid $0.2569 per share on March 30, 2026, continuing an uninterrupted quarterly schedule that stretches back to 2011. For retirees and dividend-growth investors weighing ... Why retirees are banking on SCHD’s 15-year unbroken dividend streak

Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.

Earlier this week, Merck announced that its pivotal Phase 3 TroFuse-005 trial showed sacituzumab tirumotecan significantly improved overall and progression-free survival versus chemotherapy in certain patients with advanced or recurrent endometrial cancer, also meeting a key secondary endpoint of objective response rate with no new safety concerns. This is the first global Phase 3 study in this setting where an antibody-drug conjugate outperformed chemotherapy on both survival measures,...

New 25-strain Prevnar candidate moves into final-stage testing after strong infant trial results against severe pneumonia strain.

Shares of biotech company Regeneron (NASDAQ:REGN) fell 10.5% in the afternoon session after its experimental cancer treatment failed to meet the main goal in a late-stage study for patients with a type of advanced skin cancer.

PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.